Poland · Delayed Price · Currency is PLN Munar Pharma Statistics
Total Valuation
Munar Pharma has a market cap or net worth of PLN 14.99 million. The enterprise value is 13.57 million.
| Market Cap | 14.99M |
| Enterprise Value | 13.57M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Munar Pharma has 46.98 million shares outstanding. The number of shares has increased by 176.72% in one year.
| Current Share Class | 46.98M |
| Shares Outstanding | 46.98M |
| Shares Change (YoY) | +176.72% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.59% |
| Owned by Institutions (%) | n/a |
| Float | 43.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 59.94 |
| PB Ratio | 14.36 |
| P/TBV Ratio | 14.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 54.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.43 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -12.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -69.38% |
| Weighted Average Cost of Capital (WACC) | 6.46% |
| Revenue Per Employee | 62,500 |
| Profits Per Employee | -180,504 |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.68% in the last 52 weeks. The beta is 0.35, so Munar Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -18.68% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 56.78 |
| Average Volume (20 Days) | 12,946 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Munar Pharma had revenue of PLN 250,000 and -722,016 in losses. Loss per share was -0.02.
| Revenue | 250,000 |
| Gross Profit | -1,358 |
| Operating Income | -723,800 |
| Pretax Income | -722,016 |
| Net Income | -722,016 |
| EBITDA | -729,874 |
| EBIT | -723,800 |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 1.43 million in cash and 12,529 in debt, with a net cash position of 1.41 million or 0.03 per share.
| Cash & Cash Equivalents | 1.43M |
| Total Debt | 12,529 |
| Net Cash | 1.41M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 1.04M |
| Book Value Per Share | 0.02 |
| Working Capital | 1.04M |
Cash Flow
In the last 12 months, operating cash flow was -599,872 and capital expenditures -7,113, giving a free cash flow of -606,985.
| Operating Cash Flow | -599,872 |
| Capital Expenditures | -7,113 |
| Depreciation & Amortization | -6,074 |
| Net Borrowing | -3.23M |
| Free Cash Flow | -606,985 |
| FCF Per Share | -0.01 |
Margins
Gross margin is -0.54%, with operating and profit margins of -289.52% and -288.81%.
| Gross Margin | -0.54% |
| Operating Margin | -289.52% |
| Pretax Margin | -288.81% |
| Profit Margin | -288.81% |
| EBITDA Margin | -291.95% |
| EBIT Margin | -289.52% |
| FCF Margin | n/a |
Dividends & Yields
Munar Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -176.72% |
| Shareholder Yield | -176.72% |
| Earnings Yield | -4.82% |
| FCF Yield | -4.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 10, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 10, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Munar Pharma has an Altman Z-Score of 2.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.78 |
| Piotroski F-Score | 2 |